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Abstract
Traditionally, cancer therapies are generally non-specific treatments meant to eradicate
cancer cells. This can result in death of healthy tissue, which can significantly affect the
overall well-being of the patient during and after treatment. Immunotherapy offers a more
targeted approach by using immune cells to specifically identify and kill cancer cells
through various neoantigens presented on the surface of the cancer cell. Drugs that target
and block PD-(L)1 and CTLA-4, known as checkpoint inhibitors, act to “cut the breaks”
on the immune response and keep it actively seeking out and killing cancer cells. Many
patients fail on these treatments due to a lack of CD8+ T cells, and other cytotoxic
immune cells, being called into the tumor microenvironment. Many therapies exist to
work in combination with checkpoint inhibitors to turn these immunologically “cold”
tumors “hot” and prolong an immune response. I postulated that blocking PD-1, CD47,
and SEMA4D in a novel triple combination treatment will allow for a greater presence of
CD8+ T cells into the tumor microenvironment and double the overall response rate of
patients. In a clinical trial consisting of 200 patients, half were placed into the control
receiving Pembrolizumab (anti-PD-1) and TTI-621 (anti-CD47), while the experimental
group received the triple treatment of Pembrolizumab, TTI-621, and Pepinemab (antiSEMA4D). Results indicated that the triple combination treatment was effective in
improving progression-free survival, overall survival, and overall response rate compared
to that of the control. This clinical trial supports that this triple combination treatment can
be potentially used as a cancer therapeutic in the future.
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Introduction

Summary of immuno-oncology and cold tumor concept
For decades, the leading treatment for a majority of cancers has been a triad of surgery,
chemotherapy, and radiation. These treatment options are generally non-specific towards cancer
cells and result in a massive deterioration of the patient’s healthy cells and overall quality of life.
While this blanket approach has been effective in eliminating many individuals’ cancers and
improving survivorship, there are a number of cancers that remain elusive to treatments or end
up resurging years later. Throughout the history of cancer research, there have been marked
advancements that support the fact that not every cancer is the same. Each cancer has a different
combination of multiple mutations that affect an array of aspects of the cell cycle, angiogenesis,
and anchorage dependence. Essentially, every tumor has a different mode of attack that can vary
from patient to patient, or even within the tumor itself. Because of this cancer diversity, cancer
researchers have been attempting to create more targeted therapies that will be special to a
patient’s specific type of cancer.

The human body has an incredible arsenal against cancerous growths. Heavy regulation of the
cell cycle, DNA repair mechanisms, and pro-apoptotic mechanisms all seem to exist in order to
thwart any rogue cell from establishing itself and harming the host organism. Despite the body’s
defenses against cancer, the cancerous cells can still manage to evolve and find a way to bypass
these innate checks and balances. A normal cell can become transformed via the accumulation of
mutations. Mutations specifically affecting some aspect of the cell cycle and cell growth aide in
the transformed cell securing an advantage. Cancers will also accrue more mutations over time
1

allowing them to change their tactics along the way or add in their repertoire against the body’s
defenses. This wide array of potential cancer phenotypes can seem like a perpetual arms race to
beat the cancer first thus making the development of effective treatments very difficult. In the
1980s, a relatively novel approach surfaced: Immuno-oncology (Decker et. al., 2017). Cancer
Immunotherapy is a class of treatment options that uses the host’s immune system to target, kill,
and eliminate tumor cells just as it would a foreign bacterial or viral invader. Compared to other
more traditional and broad-spectrum methods of cancer treatment, immunotherapy offers a more
targeted approach, which would improve the quality of life for the patient by reducing negative,
and potentially dangerous, side effects. Chemotherapy is a nonspecific treatment type that attacks
rapidly dividing cells. While this may effectively kill cancer cells, it can also result in severe offtarget affects – the killing of the patients’ healthy, rapidly dividing cells such as skin cells and
the lining of the digestive tract. Immunotherapy acts to target neoantigens – proteins unique to
cancer cells – recruiting various immune cell types to effectively kill and eliminate cancer cells
all over the body. Over the past three decades, the modern immuno-oncology movement has
quickly exploded and the mechanisms behind its efficacy are being researched, treatments are
being developed, and clinical trials are underway.

The Human Immune System
The human immune system utilizes an arsenal of molecular and cellular responses that work to
recognize, target, and kill foreign entities. The immune response is comprised of two major
branches – innate immune response and the adaptive immune response. Both aspects work in
tandem and are responsible for the protection of the host from foreign, pathogenic invaders, such
as bacteria and viruses, but achieve this through different mechanisms. The innate immune
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system guards against general invaders and requires no prior exposure to learn what constitutes
as a foreign invader. Elements of the innate immune system, such as macrophages, natural killer
(NK) cells, and neutrophils are pre-programmed to recognize substances that are not native to the
host body and eliminate them through phagocytosis. NK cells are essentially pre-programmed to
target cancerous cells with the ability to recognize various configurations of cell surface proteins
that identify the cancer cell. This system has a relatively quick response to non-native entities
and releases molecules, like cytokines and chemokines, to trigger inflammation. This
inflammation attracts other cell types – particularly ones involved in the adaptive immune
response.
The adaptive immune response is more of a targeted system that acts on specific
pathogens and is involved with immune memory. It is initiated by the phagocytosis of foreign
pathogens. Key phagocytic cells, namely macrophages and dendritic cells, recognize foreign
antigens – proteins presented on the surface of cells – phagocytize the invader, and cleave the
proteins into small oligopeptides (Weinberg, 2014). Once cleaved, these small protein sequences
(8-11 residues in length) are presented on a specific antigen presenting region on a Major
Histocompatibility Complex I or II (MHC-I or MHC-II) complex. (Weinberg, 2014) These
proteins on the surface of antigen presenting cells (APCs) act to bind with receptors on CD4+ T
Helper cells (TH) or CD8+ Cytotoxic T cells (TC/ CTLs). TH cells activate B cells initiating their
replication and activating their maturation. Once activated, B cells produce antibodies that can
then recognize the specific antigens throughout the body. This represents the humoral response
of the adaptive immune system. Antibodies can recognize the antigen sequences and opsonize
the invader or infected cell. This opsonization first neutralizes the target and allows for the
subsequent phagocytosis by macrophages, attraction of complement molecules, or death by
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cytotoxic T cells. CD8+ Cytotoxic T cells represent another branch of the adaptive immune
system – the cell-mediated response. Once mature, CTLs have T-cell receptors (TCRs) that
allow them to target the antigen that was presented to them. Whenever a CTL comes in contact
with an antigen recognized by its TCR, it can kill the cell triggering pro-apoptotic cascades. If
the immune system can be manipulated to target cancer cells, researchers can exploit that as a
potential treatment option.
Another aspect of the immune system, and one of the areas for promising immunotherapy
targets, involves blocking the “off” switch for the immune system. The immune system has a
natural homeostasis, so when “on” signals (such as cytokines and chemokines) are being
released, they are also stimulating the “off” signals, through negative feedback, in order to avoid
a severe overreaction of the immune system (Weinberg, 2014). These “off” signals can induce
the activation of immunosuppressive cells or immunosuppressive proteins. Regulatory T cells
(TReg) have the same antigen-specific TCRs that are also expressed by CTLs. This allows for the
TReg’s to compete with the CTLs for the MHC-I proteins on the outside of cells. In addition,
Teg’s can secrete compounds to suppress the proliferation of TH and CTLs, which enhances the
immunosuppressive action.
Regulatory T cells are not the only immunosuppressive mechanism the human immune
system can employ. Programmed Cell Death Protein -1 (PD-1) and its ligand, PD-L1, interact in
order to induce what is known as T cell exhaustion, which results in an inhibition of T cell
activation and proliferation. PD-L1 is generally not detectable in normal tissue, but an IFN
gamma response can cause normal cells to upregulate its expression (Simon and Labarriere,
2017). Some tumor cells have evolved to express PD-L1 in order to block T cell
activation/proliferation and go unnoticed by T cells thus evading destruction.
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Checkpoint inhibitors, such as anti-PD-(L)1 and anti-CTLA-4, act to block the pathway
that regulate the “off” switches of the immune system. This allows the attack cells of the immune
system to continue working at targeting the tumor cells without a negative regulator. Current
FDA approved checkpoint inhibitors currently on the market include Anti-PD-1 drugs, such as
Nivolumab (Opdivo ®) and Pembrolizumab (Keytruda ®), Anti-PD-L1 drugs like
Atezolizumab, and Anti CTLA-4 drugs like Ipilimumab (Yervoy ®).
Since there are many players in the immune system, there are many potential targets for
immunotherapy. However, just as with other molecular or cellular defenses, cancer evolves yet
another way to circumvent the body’s defenses. Unfortunately, not all patients respond to
checkpoint inhibitors. The efficacy of the checkpoint inhibitor treatment is dependent on the
tumor’s microenvironment (TME), particularly the presence of certain immune cells, such as
CD8+ Tumor-Infiltrating Lymphocytes (TILs) and PD-L1 expression (Gulfo, 2018). Without
these cells or protein markers present in the tumor environment, the tumor will not be recognized
by the body’s immune system. This is referred to as an immunologically “cold” tumor and will
therefore escape destruction. The TME can be classified into four main types: Type I – IV. An
immunologically “hot” tumor is one that exhibits a Type I phenotype (Gulfo, 2018). This TME is
TIL+ and PD-L1+ providing an ideal environment for a checkpoint inhibitor. Blocking PD-(L)1
keeps the immune system revved up and continually targeting and attacking tumor cells. This is
possible with TILs already present in the TME – they will continually attack the tumor cells,
effectively shutting off the negative regulation of an immune response. An immunologically
“cold” tumor does not have a TME that attracts TILs. Patients that do not respond to checkpoint
inhibitors typically fall into the Type II- Type IV profiles. The key to an effective checkpoint
inhibitor is maintaining or triggering a “hot” TME (Gulfo, 2018).

5

How to turn a cold tumor hot – different approaches
The immune system has a natural homeostasis that regulates its response. It takes a combination
of signals from various cell types to elicit an immune response as well as numerous negative
regulators to turn off a response. Because of this natural system of checks and balances, it can be
difficult to manipulate a particular response with only one approach. Combination approaches
(Checkpoint inhibitors + another immune target) are being researched for efficacy in cancer
treatments (Gulfo, 2018). Different targets can be used to initiate a type I interferon response,
while the checkpoint inhibitors prevent the negative regulation of the natural immune system.
This continual immune response can then be used to target cancer cells throughout the body.
Major therapy types include other checkpoint inhibitors (immunomodulators), cancer vaccines,
oncolytic viruses, CD3 Targets bispecific monoclonal antibodies (mAb), adoptive T cell transfer,
Monoclonal antibodies, or targeted fusion proteins.
LAG-3
LAG-3 is a surface receptor expressed on activated T Cells (Burugu et al., 2018). Binding of
LAG-3 with its ligand will act as an immune suppressant by influencing the activity of Tregs and
cytotoxic T cells. When bound to Major Histocompatibility Complex II (MHCII) class proteins,
Treg activity and proliferation is enhanced. When bound with LAG-3 on Cytotoxic T cells,
proliferation and cytokine production are reduced, thus supporting an immunosuppressive action
(ct). Cancer cells can increase their production of MHCII production in order to exploit this
immunosuppressive mechanism. Blocking LAG-3 diminishes the number of Tregs and restores
the CD8+ effector T cells, counteracting the immunosuppressive activity and maintaining the
type I tumor microenvironment for effective checkpoint inhibition. When working in
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combination, the effects are enhanced with anti PD-1 as evidenced in various clinical trials
(Burugu et al., 2018).
TIM-3
TIM-3 is an immune-inhibitory molecule first found on CD4+ T Helper cells and CD8+ T
Helper cells. Binding of its ligand, galectin-9, leads to effector T cell death resulting in immune
tolerance – exhausted T cells. Conversely, ligand binding on Regulatory T cells results in an
enhanced immunosuppressive action. Blocking of this pathway, when combined with anti PD-1
therapy, has produced effective results (Burugu et al., 2018).
TIGIT
TIGIT is a transmembrane protein receptor that regulates the immune checkpoint on T and NK
cells. When ligands (CD155, CD112, and Nectin 2) bind, effector functions are inhibited in part
by the production of IL-10. This immunosuppressive cytokine is responsible for the expression
of the M2 macrophage phenotype, which is representative of more of an anti-inflammatory
profile (Chen et al., 2016 and He et al., 2017).
B7-H3 (CD 276)
This ligand belonging to the B7 family of molecules that are frequently overexpressed in many
types of cancers (Burugu et al., 2018). This can be a critical and desirable cancer target/marker
since it is lacking in healthy tissue. Recent studies have shown that this family of molecules is
involved in immunosuppressive activity correlated to the increase in production of Interleukin –
10 (IL-10) and TGF-b as evidenced by Sai Han et al in cervical cancers (Sai Han et al., 2018).
Functioning in tandem with CTLA-4 and PD-1, the B7-H3 class of molecules can also work to
suppress T cell activation and proliferation further supporting it as an ideal checkpoint target. In
addition to its immunosuppressive qualities, B7-H3 molecules have also been found to
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upregulate the cell cycle in tumor cells, support angiogenesis, and allow for metastasis of various
tumor types (Burugu et al., 2018 and Castellanos et al., 2017).
GITR
GITR is a type II transmembrane receptor found extensively on regulatory T cells, and in lower
amounts on other immune cells such as effector T cells (Knee et al., 2016). Binding to its ligand
(GITR-L) inhibits regulatory T cell function by inducing depletion of these cell types and
activates effector T cells (Burugu et al., 2018 and Knee et al., 2016).
CD47 and SIRPa
CD47 is a cell surface immunoglobulin that negatively regulates anti-tumor immunity through
suppression of phagocytosis via the SIRPa receptor on macrophages (Burugu et al., 2018).
CD47 is expressed on nearly all cell lines, including cancer cells, and is used and exploited by
cancers as a “don’t eat me” signal. When CD47 found on the surface of a red blood cell binds to
the SIRPa receptor on the macrophage, it triggers intracellular downstream effectors that inhibit
phagocytosis (Burugu et al., 2018). To the macrophage, that cell has identified itself as
something not to “eat.” Cancer cells can exploit this mechanism and express CD47 on their cells.
This tells the innate immune system to pass by, thus evading destruction. Blockade of the
CD47/SIRPa interaction through the synthesis of monoclonal antibodies induces phagocytosis of
cancer cells (Murata et al., 2018).
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IDO
IDO is an intracellular enzyme that is found in macrophages and dendritic cells that converts
tryptophan to kynurenine (Burugu et al., 2018). Less cytosolic tryptophan translates to less T cell
proliferation. More kynurenine induces apoptosis of TH1 cells and promotes differentiation of
TH1 cells to T regs. Blocking of IDO results in an increase in T cell response and inhibits tumor
progression (Burugu et al., 2018). BIN1 is a tumor suppressor that controls expression of IDO
and is deficient in numerous cancers.

KIR Family (Killer immune-globulin-like receptor)
This family of receptors is expressed on most NK cells and some T cells (Burugu et al., 2018).
Some are inhibitory when they bind to MHC molecules (HLA-C/HLA-B), while those on NK
cells, are used to identify against self-recognition (Burugu et al., 2018). This is an effective tool
for the cancer since cancer cells are considered to be “self” thus making the targeting of these
rogue cells difficult. Despite this, inhibiting the KIR receptors and HLA ligands that elicit an
inhibitory response, the NK activation signals can be bypassed (Burugu et al., 2018).

CD94/NKG2A
On T cells, this receptor functions as an inhibitory checkpoint and blocking it with The IPH2201
antibody, can improve antibody-dependent cell cytotoxicity (Burugu et al., 2018). Many cancers
have elevated NKG2A+ NK cells such as an increase in NKG2A in lung and cervical tumors
compared to the periphery (Burugu et al., 2018). The highest expression is found in cancers with
low CD8+ TILs and Ki67 (Burugu et al., 2018).
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TLR-9
TLR-9 recognizes a known pathogen signatures (PAMPs) by binding to single stranded
unmethylated CpG-DNA and induces an inflammatory response in an effort to enhance
cytotoxicity by way of IFNa expression (Gulfo, 2018). It also induces antigen expression that is
needed to attract CD8+ TILs making it a desirable target to turn an immunologically cold tumor
hot. (Gulfo, 2018).

DKK
Promotes an immune-suppressive tumor microenvironment by increasing the MDSC (Myeloid
derived tumor suppressor cells) resulting in a suppressed T cell response (D’Amico et al., 2016).
Another immunosuppressive action of DKK includes a decrease in NK activating ligands on
tumor cells (Malladi et al., 2016). A decrease in these ligands will reduce interaction with tumortargeting NK cells. DKK also increases Th2 polarization and decreases IFNa production all to
achieve an immunosuppressive tumor microenvironment (Chae et al., 2016).

Agnostic mAbs targeting APCs (Antigen presenting Cells) – CD40
CD40 is expressed broadly on APCs including DCs, B cells, and monocytes. Antibodies
targeting CD40 promotes DC maturation and cross-presentation of antigens to T cells. It also
induces apoptosis of tumor cells and TAM conversion to M1-like macrophages (Ishihara et al.,
2018).
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DC vaccines
Dendritic cells are antigen-presenting cells that can be utilized in the regulation of the immune
response. This provides a workable mechanism to derive vaccines that can be used to enhance
tumor antigen presentation to T cells (Mastelic-Gavillet et al., 2019). They are generated ex vivo
and pulsed with specific peptides (protein or whole tumor lysate) and can be used in combination
with anti-PD-(L)1 or anti-CTLA4 (Mastelic-Gavillet et al., 2019).

Macrophage reprogramming
Tumor Associated Macrophages are highly immunosuppressive. Antibody blockade of the
receptor for colony stimulating factor 1 (CSF-1) – highly expressed by TAMs – can reprogram
them toward an M1 phenotype (Räihä and Puolakkainen, 2018). M1-like macrophage is desired
for its enhanced antigen presentation, promotes stronger anti-tumor T cell responses and
synergizes with checkpoint blockade (Räihä and Puolakkainen, 2018).

Immunogenic chemotherapy
Promotes immunogenic cell death (ICD) through presentation of “eat me signals” via the
translocation of the chaperone proteins, calreticulin, from the endoplasmic reticulum to the
surface of the tumor cells leading to the activation of DCs and recruitment of TILs (Wu and
Waxman, 2018).

11

Oncolytic viruses
The use of oncolytic viruses results in the direct killing of tumor cells. These viruses can be
designed to specifically target cancer cells and result in the induction of innate and adaptive
immune response (Kaufman et al., 2015). Upon infection, tumor cells release ROS and Type I
IFNa; upon lysis, DAMPs and PAMPs. Oncolytic viruses such as in the drug, T-VEC, have been
gene edited to integrate immunomodulatory genes like cytokines, chemokines, and T-cell
stimulatory molecules (Kaufman et al., 2015).
Targeting tumor vasculature
Tumor vasculature normalization allows the vessels to be more permissive to tissue perfusion
and delivery of oxygen, drugs, Antibodies, and T cell infiltration following treatment (Lanitis et
al., 2015). This treatment type also increases leukocyte adhesion molecules (ICAM-1 and
VCAM-1), which are anti-VEGFR and anti VEGFR mAbs, and increases chemokines and
cytokines like IL-10, TNF-a, and CXCL10 which leads to increased lymphocyte infiltration
(Lanitis et al., 2015).

CAR T cells
Immune cells that are removed from the patient are then engineered and armed with new proteins
that have the ability to recognize the cancer. Then, this newly design T cell is given back to the
patient. Targets antigens found on B cells – CD19 – however, mesothelin (expressed on solid
tumor cells) could be a potential target for solid tumors (Adusumilli, 2017) (Newick et al., 2016).
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NK Cell activation/mobilization
The NK activating receptor is CD16 along with other cell surface receptors. Antibodies can be
developed to activate this receptor thus activating NK cells and allowing them to target cancer
cells without prior antigen presentation (Sharma et al., 2017).

Combined Treatment Responses
While checkpoint inhibitor treatments and cold tumor treatment have allowed for
improved treatment response and survival compared to checkpoint inhibitor treatment alone,
response rates are still relatively low (~30%) leaving most patients unresponsive to this
combination treatment (Trillium Therapeutics, 2019). A recent combination trial run by Trillium
Therapeutics, has their anti-CD47 drug – TTI-621 – exhibiting a > 50% reduction in CAILS in
41% of patients (Table 1). The Composite Assessment of Index Lesion Severity (CAILS) ranks
five aspects of lesion morphology including erythema, scaling, plaque elevation, hypo- or
hyperpigmentation, and lesion size from 0 to 8. A CAILS score is a method of measure for a
lesion severity and is commonly used to indicate efficacy of treatments (Olsen et al., 2011).
While these results are a significant advance in cancer immunotherapy, it does not provide
significant results in a majority of patients.
Table 1
Drug

Response Rate (%)

TTI-621(Trillium)
41% with a > 50% reduction in
+
CAILS
anti-PD-1/PD-L1
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According to Evans et. al. in association with Vaccinex, a class of molecules called
Semaphorins have been shown to alter cytoskeletal effects of immune cells, endothelial cells,
and tumor cells influencing how they navigate around the TME. Restricted immune cell access
into the TME may explain why many other cancer immunotherapy treatments fail.
Semaphorins are soluble, transmembrane proteins that are ubiquitous throughout immune
cells, but have been linked to overexpression on certain cancers. Expression of a particular
member of the semaphorin class – SEMA4D – has been shown to be triggered by hypoxia and
other factors that are characteristic of the TME and inhibits the movement of immune cells
(Evans et al., 2015). According to Evans et. Al., SEMA4D acts as a physical barrier that
surrounds tumors, subsequently preventing CD8+ T cells from entering the tumor. If TILs are
prevented from accessing the TME, then they cannot cause any damage to the tumor cells. So,
while there may be an increase in TILs activated by APCs, if they cannot enter the TME then
their cytotoxic effects are restricted. As evidenced by Vaccinex, SEMA4D is localized to the
outer rim of the tumor bed. CD8+ T cells are blocked from entering the TME as evidenced by
their accumulation around the tumor margin and relatively low concentration within the tumor
bed. Allowing for increased immune infiltration into the TME may result in more effective
responses. Vaccinex has shown in clinical trials that patients respond to treatment with antiSEMA4D4 (Pepinemab). Treatment with anti-SEMA4D/Mab67 (Pepinemab) effectively breaks
down the barricade allowing a greater infiltration of cytotoxic immune cells.
In addition to breaking down the physical barrier SEMA4D creates, Pepinemab treatment
and a checkpoint inhibitor (Avelumab) also influences the CD8+ T cell to Regulatory T cell
ration (Teff : Treg) (Preston et al., 2013). Anti-SEMA4D treatment promotes an inflammatory
response by increasing infiltration of CD8+ T cells and downregulates the expression of
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Regulatory T cells. These findings not only support that SEMA4D acts as a physical barrier, but
also that it suppresses an inflammatory response via the regulation of Treg cells.

Concluding Statement
Checkpoint therapy has provided unprecedented results for a relatively small number of patients.
It works by preventing the homeostatic mechanisms that act to shut-off of the patient’s immune
system. In a normal and healthy patient, this regulatory mechanism works to prevent an
overreaction of the immune system. Cancer cells can exploit this and overexpress either the
ligands or receptors responsible for silencing immune cells. When treating cancer cells,
preventing the function of immune system regulators allows for the cytotoxic immune cells to
work longer on tumor cells effectively eradicating them. However, in order for checkpoint
inhibitors to be effective, the tumor must be considered immunologically hot, that is have a
strong interferon gamma signal, that calls various cytotoxic cells to the tumor microenvironment.
A variety of methods have been employed to turn cold tumors hot and have shown to be
effective working in combination with a checkpoint inhibitor. Combination treatments work in
harmony to both call immune cells to the microenvironment and keep the immune system revved
up to continually target and kill the tumor. Despite the strides made and the dramatic results of
combination treatments, there are still patients who are unresponsive to treatment indicating that
the cancer has evolved yet another way to survive and successfully propagate. Recent studies
have assessed the impact of the presence of SEMA4D on the surface of cancer cells –
specifically at the tumor bed boundary – effectively acting as a physical barrier preventing T
cells from entering the tumor. This is an intriguing aspect to investigate and may provide an
explanation as to why combination treatments do not work for a majority of patients. Patients
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who do not respond to anti-CD47 and anti-PD-1 combination treatment typically fail in the noninjected lesions, while there is success in the injected lesions. This indicates that there is a
sufficient immune response to eradicate the tumor. However, I postulate that non-injected tumors
are not receiving this large immune response because of the SEMA4D blockade. If there is a
physical barrier at the edge of the tumor bed preventing access of immune cells into the tumor
microenvironment, then all other efforts to attract cytotoxic cells or keep the immune system
revved up are futile. I am postulating that the blocking of SEMA4D, in combination with
checkpoint inhibitors and anti-CD47, will then allow the tumor microenvironment to sustain a
prolonged immune response and double the response rate of patients who otherwise were
unresponsive to other combination immunotherapies. I am postulating that the augmented effect
will be mediated by an increase in CD8+: Treg ratio in the tumor microenvironment.
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Research Design and Methods
Experiment 1 – Effect of Treatment on Melanoma with Checkpoint Inhibitor,
Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Anti-SEMA4D
Pepinemab combination treatment

10 mg/kg of
Pembrolizumab and the
TTI-621 anti-CD47
treatment

Subjects:
Histologically confirmed
subcutaneous metastatic
melanoma (stage IIIA,IIIB,
or IIIC) exhibiting resistance
of Pembrolizumab
(Keytruda ®) after four
failed months of anti-PD-1
therapy

N = 200

10 mg/kg of
Pembrolizumab, TTI-621,
and Pepinemab (antiSEMA4D) treatment

Figure 1 – Clinical Trial Design
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Subjects
A sample of 200 total patients, 18 years of age or older, with histologically confirmed cutaneous
melanoma with metastasis to regional lymph nodes and who also exhibit resistance to
Pembrolizumab (Keytruda ®) were recruited. The patients had to have either stage IIIA
melanoma, stage IIIB, or stage IIIC disease with no in-transit metastases as defined by the
American Joint Committee on Cancer 2009 classification, 7th edition. Resistance to
pembrolizumab indicated after four failed cycles (4 months) of previous anti-PD1 therapy. A
tumor sample from melanoma-positive lymph nodes was required to be sent for central
pathological evaluation of PD-L1 expression. Membranous expression of PD-L1 in tumor was
assessed by means of a clinical trial immunohistochemistry assay (22C3 antibody) and was
scored on a scale of 0 to 5. A score of 2 was considered to indicate PD-L1 positivity.

Trial Design
One hundred of the recruited patients were randomly placed in one of two cohorts: the control,
which will receive 10 mg/kg of Pembrolizumab and the TTI-621 anti-CD47 treatment, and the
experimental, which will receive 10 mg/kg of Pembrolizumab, TTI-621, and Pepinemab the antiSEMA4D treatment. The patients received this dose every 4 weeks for a total of 12 doses
(approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. The
rules regarding the withholding of a dose of either the control or experimental treatment and the
management of immune-related adverse events are detailed in the protocol, available at
NEJM.org. The primary end point was progression-free survival. Secondary end points included
overall survival, ratio of CD8+ T cells to FoxP3 T regulatory cells, safety measures, and
measures of health-related quality of life (Eggermont et al., 2018) (Preston et al., 2013).
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Assessments and Clinical Endpoints
Computed tomography (CT), magnetic resonance imaging (MRI) or both were performed every
12 weeks for the first 2 years. Progression or metastatic lesions had to be histologically
confirmed whenever possible. The initial date of progression was also recorded.
Progression-free survival
The number of months patients survive without further progression of the disease from the time
of randomization until the date of first local, regional, or distant metastasis.
Overall Survival
The number of months patients survive from the time of randomization until the date death from
any cause.
Overall Response Rate
The response rate will be calculated from the number of complete responders plus the number of
partial responders in both the control and experimental cohorts.
Ratio of CD8+ T cells to FoxP3 T regulatory cells
The number of CD8+ T cells and CD4+CD25+FoxP3+ will be quantified and analyzed using
staining and immunofluorescence analysis of tissue specimens, confocal microscopy, cell
quantification, tumor-infiltrating lymphocyte isolation, and flow cytometry.
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Safety
Adverse effects were assessed at every CT/MRI session with the use of the National Cancer
Institute Common Terminology Criteria for Adverse Events, version 4.0, and included a
complete physical examination along with hematological tests. Immune-related adverse effects
were determined from the Medical Dictionary for Regulatory Activities terms, which is
periodically updated.

Consent
All methods and protocols were outlined for the patient’s understanding and approval. After the
patients review all necessary features of the clinical trial, written consent was obtained. Patients
were told that they can withdrawal from the clinical trial at any time for any reason. The entire
procedure was aligned with the guidelines outline by the Institutional Review Board (IRB) at
Seton Hall University.

Demographic information
Patient demographic information was collected from each individual’s personal case-report form.
Details on sex, age, body mass index (BMI), disease stage, type of lymph node involvement,
number of positive lymph nodes on pathological testing, ulceration, and PD-L1 expression
status.
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Statistical Analysis
Progression-free survival was estimated with the Kaplan-Meier method. Comparisons between
the two cohorts were made using log-rank tests at two-sided alpha level. Cox proportionalhazards model was used to estimate the hazard ratio and its respective confidence interval
(>95%). All analyses were made with SAS software, version 9.4. Power calculations were
performed using East Software, version 6.4 (Cytel). A P-value of <0.05 is considered to be
statistically significant.

Results
Combination treatment with checkpoint inhibitor, Pembrolizumab (Keytruda ®), Anti-CD47
TTI-621 (Trillium), and Anti-SEMA4D Pepinemab doubles the response rate of patients
Patients and Trial Regimen
A total of 200 patients underwent treatment in two cohorts: combination treatment with
Pembrolizumab (Keytruda ®) and Anti-CD47 TTI-621 (Trillium) or Pembrolizumab (Keytruda
®), Anti-CD47 TTI-621 (Trillium), and Pepinemab. Upon initial analysis of patient
demographics, looking at sex, age, body mass index, disease stage, type of lymph node
involvement, ulceration, and PD-(L)1 expression (Table 2), the characteristics were found to be
similar in the two groups.

Efficacy
The 24-month progression-free survival median was not reached in the experimental
group with Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Pepinemab
treatment (Table 3, Fig. 3). The progression-free survival median was 9 months in the control
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group with Pembrolizumab (Keytruda ®) and Anti-CD47 TTI-621 (Trillium). Progression-free
survival was significantly higher in the experimental group compared to the control treatment
(Table 3, Fig. 3) indicated by the hazard ratio. The hazard ratio for progression-free survival was
0.4 indicating that there were significantly fewer deaths in the experimental group than there
were in the control group. Same was true for overall survival where the hazard ratio was 0.25,
the overall survival median was 20.4 months for the control and again, not reached for the
experimental treatment. The overall response rate for the experimental treatment was 63%, more
than triple that of the control, which was only 20%. (Table 3).
In addition to overall response rate, overall survival, and progression-free survival, we
looked for a mechanism behind the results. Across all patients, the average ratio of CD8+ T cells:
CD4+CD25+FoxP3+ regulatory cells was significantly higher in the patients receiving
Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Pepinemab treatment
compared to the control (0.98 compared to 0.32). The same held true when comparing the ratios
of CD8+:CD4+ T cells (0.27 compared to 0.13 in the control) (Table 4).

Safety
Adverse effects of any grade considered to be in connection with the trial were assessed
and occurred in 25% of patients in the experimental group and 37% in the control group (Table
5). The rates of fatigue or asthenia and of diarrhea were similar in the two trial groups. Adverse
events of grade 3, 4, or 4 that were related to the trial regimen occurred in about the same
number of patients in the triple combination group as in the control. Other immune-related
adverse events of any grade occurred in roughly the same number of individuals with the most
common being hypothyroidism found predominantly in the experimental group (Tables 5 and 6).

22

Table 2 – Demographic and Clinical Characteristics of Patients at Baseline.
Pembrolizumab
+ TTI-621+

Characteristic

Pepinemab
(N = 100)

Pembrolizumab
+ TTI-621
(N = 100)

Sex
Male

63

60

Female

37

40

Median

54

54

<50 yr

37

37

50 – <65 yr

38

38

>65 yr

25

25

<25

31

37

25 - <30

45

39

> 30

24

24

Stage IIIA

16

16

Stage IIIB

46

46

Stage IIIC with 1 – 3 positive lymph nodes

19

18

Stage IIIC with > 4 positive lymph nodes

19

20

Stage IIIA

15

15

Stage IIIB

47

46

Stage IIIC with 1 – 3 positive lymph nodes

17

19

Stage IIIC with > 4 positive lymph nodes

21

20

36

32

Age

Body-mass Index

Disease Stage at Randomization

According to AJCC 2009 Criteria

Type of lymph node involvement
Microscopic

23

Macroscopic

64

68

1

44

47

2 or 3

34

33

>4

22

20

Yes

40

39

No

45

50

Unknown

15

11

Positive

84

85

Negative

11

11

Indeterminate

5

4

No of Positive lymph nodes on pathological testing

Ulceration

PD-L1 Expression Status

24

Table 3 – Efficacy Results

Endpoint

Pembrolizumab +
TTI-621+
Pepinemab
10 mg/kg every 4
weeks
(N = 100)

Pembrolizumab
+ TTI-621
10 mg/kg every 4
weeks
(N = 100)

NR

20.4 months

Overall Survival (OS)
Median
Hazard Ratio (95% CI)
p-Value (Stratified log rank)
Progression-Free Survival (PFS)
Median
Hazard Ratio (95% CI)
p-Value (Stratified log rank)
Overall Response Rate (ORR)
ORR (95% CI)
Complete Response Rate
Partial Response Rate

0.25
<0.0001
NR

9 months
0.4
<0.0001

63%
25
38

20%
2
18

Table 4 – Comparisons of T Cell Ratios.

Ratios
CD8+/CD4+
CD8+/CD4+CD25+FoxP3+

Pembrolizumab + TTI621+ Pepinemab
10 mg/kg every 4 weeks
(N = 100)
Median
0.27
0.98

25

Pembrolizumab +
TTI-621
20 mg/kg every 4 weeks
(N = 100)
Median
0.13
0.32

p-Value
0.050
0.027

Table 5 – Adverse Reactions Occurring in >10% of Patients

Adverse Reaction

Pembrolizumab + TTI621+ Pepinemab
200 mg every 4 weeks
(N = 100)
All Grades Grades 3-5

Pembrolizumab + TTI621
200 mg every 4 weeks
(N = 100)
All Grades Grades 3-5

General
Fatigue
Pyrexia
Metabolism and Nutrition
Decreased Appetite
Respiratory, Thoracic, and Mediastinal
Dyspnea
Cough
Skin and subcutaneous tissue
Rash
Gastrointestinal
Constipation
Diarrhea
Nausea
Endocrine
Hypothyroidism
Infections
Pneumonia
Investigations
Weight Loss

25
10

3
0

33
8

4
0

17

2

21

2

17
16

2
0

11
11

1
0

15

1

8

0

12
12
12

0
1
1

21
12
32

1
1
1

12

0

2

0

12

7

9

6

10

1

7

0
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Table 6 – Laboratory Abnormalities Worsened from Baseline in > 20% of Patients.
Laboratory Test

Chemistry
Hyperglycemia
Increased ALT
Hypoalbuminemia
Increased AST
Hyponatremia
Increased alkaline phosphatase
Hypocalcemia
Hyperkalemia
Increased prothrombin INR
Hematology
Anemia
Lymphopenia

Pembrolizumab + TTI-621+
Pepinemab
200 mg every 4 weeks
(N = 100)
All Grades
Grades 3-4

Pembrolizumab + TTI621
200 mg every 4 weeks
(N = 100)
All Grades Grades 3-4

52
33
33
31
31
29
25
23
21

5
5
2
3
9
2
3
3
2

51
32
29
32
32
29
19
20
15

5
3
1
2
8
0
1
2
3

43
30

4
7

79
41

19
13
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Progression-Free Survival (%)

Figure 2 – Kaplan – Meier Curve for Progression-Free Survival

______ Experimental
______ Control

Time in Months
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Discussion
Combination immunotherapies have shown to be efficacious in treating many cancers, however,
there is still a relatively low response rate indicating that there must be another element that is
preventing tumors from being eliminated. In order for cells from both the innate and adaptive
immune branches to target and kill cancer cells, they must gain access into the tumor
microenvironment. SEMA4D is a member of a class of receptors found on many immune cells,
but is also exploited by many cancers, that has the ability to cause cytoskeletal changes on other
immune cells effectively blocking their function and access to the tumor. So, while combination
checkpoint inhibitor therapeutics like Pembrolizumab (Keytruda ®) or Ipilimumab (Yervoy ®)
may be effective in bypassing homeostatic mechanisms of the immune system, if the immune
cells cannot physically enter the tumor microenvironment, then these treatments will not show
results since they are not targeting one of the major issues. This study postulated the effect of
blocking SEMA4D in conjunction with the combination therapies in order to break down the
physical barrier giving immune cells continued access to the tumor microenvironment. It was
hypothesized that this triple combination approach would double response rates and be mediated
by the increase in CD8+ T cell to Regulatory T cell ratios.
Results indicate that the overall response rates tripled, and progression-free survival and
overall survival increased significantly as well. The chances of progression-free survival in the
experimental group was 60% higher than that of the control and overall survival was 75% higher
compared to the control. The experimental group also had a significantly stronger overall
response rate compared to that of the control indicating that these data provide evidence to
support that this triple immunotherapy treatment is more effective in treating melanoma
compared to other adjuvant therapies. The differences in adverse effects between the two cohorts
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were statistically insignificant indicating that this new triple treatment approach is not more or
less toxic than conventional adjuvant therapies. The demographic information also supports that
any differences in results between the two groups is due to the different treatment methods and
not attributed to any other factor.
The cytotoxic T cell to regulatory T cell ratio also increased in the experimental group
indicating that more T cells are accessing the tumor bed and fewer regulatory T cells are present
and acting as a negative control for the immune response. Since SEMA4D has been found to
bind to T cells and influence their cytoskeletal movement, it can determine what cells are able to
infiltrate the tumor bed. In order to understand the mechanism behind the improved survival
rates among patients, we looked at the number of effector T cells compared to the number of
regulatory T cells. The number of effector T cells increased in the cohort receiving
Pembrolizumab (Keytruda ®), Anti-CD47 TTI-621 (Trillium), and Pepinemab treatment. This
was expected since blocking the SEMA4D receptor prevents the altered movement of infiltrating
T cells thus allowing them to move into the tumor microenvironment.
To determine how anti-SEMA4D affected T cell movement, we first calculated
the ratio of CD8+/CD4+ T cells. CD4+ represent all T helper cells, which includes regulatory T
cells. T helper cells are responsible for the release of cytokines that can both promote and shut
off an immune response by activating or inactivating certain immune players. The ratio of
CD8+/CD4+ T cells was larger in the experimental cohort compared to the control as expected.
This increased ratio indicates that there are more cytotoxic CD8+ T cells compared to CD4+ T
helper cells. In order to further narrow down the mechanism, we looked specifically at the
CD8+/regulatory T cells (CD4+CD25+FoxP3+) ratio where we also see a significant difference
between the two groups with more cytotoxic CD8+ T cells present after therapy with anti-
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SEMA4D. These data suggest that anti-SEMA4D works by allowing for an increased infiltration
of cytotoxic T cells effectively suppressing the functioning of regulatory T cells that would
otherwise downregulate the immune response.
The results of this clinical trial support the importance of the presence of TILs into the
tumor microenvironment. Anti-SEMA4D, in combination with other immunotherapies, has
shown to be an effective defense against the tumor’s effort to shut off the host immune system.
Based off of these results, this clinical trial can be expanded and increase sample size to 1,000
individuals for study. Further study may also be done in other cancers as well as determining the
exact molecular cascade mechanism SEMA4D uses to affect T cell migration. This may be
useful in the development of future therapeutics.
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